SI
EWTX icon

Sofinnova Investments’s Edgewise Therapeutics EWTX Stock Holding History

Sofinnova Investments’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-320,400
Closed -$7.05M – 71
2025
Q1 		$7.05M Buy
+320,400
New +$8.41M 0.46% 46

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments's EWTX Position: Q2 2026 in Review

Sofinnova Investments reduced its Edgewise Therapeutics (EWTX) stake by 1.4% in Q2 2026, selling an estimated $192K and leaving 380,923 shares worth $15.5M. The position accounts for 0.8% of the portfolio, ranked #33.

Sofinnova Investments first reported a position in EWTX in Q2 2024 and has held it in 9 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Sofinnova Investments held 380,923 shares of Edgewise Therapeutics worth $15.5M as of Q2 2026.
  • Sofinnova Investments sold 5,575 Edgewise Therapeutics shares in Q2 2026, an estimated $192K.
  • Edgewise Therapeutics made up 0.8% of Sofinnova Investments's portfolio in Q2 2026, its #33 holding.
  • Sofinnova Investments first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.